MedTrace Logo

Dexmedetomidine on Tourniquet Induced -Systemic Effects

NCT04307290 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-03-13

No results posted yet for this study

Summary

Eighty patients were randomly assigned to either control (CON) or dexmedetomidine (DEX) group. DEX group received a loading dose of 0.5 µg/ kg of intravenous dexmedetomidine over 10 minutes, followed by a continuous infusion of 0.5 µg/kg/h until completion of the surgery. CON group received the same calculated volume of normal saline. Pain outcomes, metabolic and coagulative changes after tourniquet application, and after tourniquet release were investigated.

Conditions

  • Arthropathy of Knee
  • Spinal Anesthesia
  • Tourniquet
  • Ischemia-reperfusion Injury

Interventions

DRUG

Dexmedetomidine Hydrochloride, or Saline

drug infusion from 10 min before the start of surgery to the end of surgery

Sponsors & Collaborators

  • Wonkwang University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-03
Primary Completion
2020-02-10
Completion
2020-03-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04307290 on ClinicalTrials.gov